Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

Company Overview

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.10 to $1.10
• 50-Day Range: $1.04 to $1.11
• 52-Week Range: $0.59 to $8.08
• Volume: N/A
• Average Volume: 701,788 shs
• Market Capitalization: $36.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STSA Stock Analysis - Frequently Asked Questions

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) announced its quarterly earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09.

When did Satsuma Pharmaceuticals IPO?

Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Satsuma Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Regional Banks
• Current Symbol: NASDAQ:STSA
• CIK: 891106
• Web: www.satsumarx.com
• Phone: 650-410-3200
• Fax: N/A
• Employees: 21
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.24%
• Return on Assets: -102.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.44
• Quick Ratio: 7.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 33,150,000
• Free Float: 22,809,000
• Market Cap: $36.47 million
• Optionable: Not Optionable
• Beta: 0.10